Gamma Knife® radiosurgery for recurrent intracranial olfactory neuroblastoma (esthesioneuroblastoma): a case report by Eduard B Dinca et al.
JOURNAL OF MEDICAL
CASE REPORTS
Dinca et al. Journal of Medical Case Reports 2012, 6:240
http://www.jmedicalcasereports.com/content/6/1/240CASE REPORT Open AccessGamma KnifeW radiosurgery for recurrent
intracranial olfactory neuroblastoma
(esthesioneuroblastoma): a case report
Eduard B Dinca, Matthias W Radatz, Jeremy Rowe and Andras A Kemeny*Abstract
Background: We report the use of salvage radiosurgery to manage an aggressive olfactory neuroblastoma
(esthesioneuroblastoma) with multiple recurrences and intracranial extension.
Case presentation: A 43-year-old Caucasian woman presented 11 years ago with progressive nasal blockage and
headaches. A necrotic polyp originating in her left middle meatus and extending to the ethmoid air cells and
cribriform plate (Kadish stage C) was radically resected via a craniofacial approach. Four years later, a local
recurrence extending into her left cavernous sinus was identified and deemed inoperable. She received vincristine,
ifosfamide, doxorubicin and etoposide chemotherapy (with minimal benefit) and external beam radiotherapy (60Gy
in 30 fractions) to her skull base. Two years later, tumour extension in her left neck was treated with radical
radiotherapy. She developed visual disturbances in her left eye, which progressed to blindness in the next two
years. Having exhausted chemoradiotherapy, the left cavernous sinus esthesioneuroblastoma was treated with
Gamma KnifeW radiosurgery 2 years ago (20Gy at 50% isodose, tumour volume 7.5cm3). At one year, there was
dramatic reduction in the tumour and no new symptoms; however, there were new tumour foci (in her left frontal
lobe and above her right orbital apex). These were again treated with radiosurgery (20Gy at 50% isodose, total
tumour volume 0.67cm3). Repeat imaging at six months showed no further disease progression.
Conclusion: Whilst rare, olfactory neuroblastoma (esthesioneuroblastoma) can present management challenges
and Gamma KnifeW radiosurgery may prove a useful strategy in controlling intracranial spread.Background
We report radiosurgical management for the intracranial
component of an aggressive olfactory neuroblastoma
(esthesioneuroblastoma) with multiple recurrences. This
minimally invasive technique was used as a ‘last resort’
for a patient who had already exhausted the available
surgical and chemoradiotherapy options.
Case presentation
Our patient, a 43-year-old Caucasian woman, first pre-
sented 11 years ago with nasal blockage and headaches,
originally thought to be due to her ongoing in vitro
fertilization treatment. A necrotic polyp originating in
her left middle meatus and extending superiorly to the
ethmoid air cells and the cribiform plate (Kadish stage* Correspondence: aakemeny@gmail.com
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reproduction in any medium, provided the orC) was resected through a craniofacial approach. Four
years later, a local recurrence extending into her left cav-
ernous sinus was identified. As it was deemed inoper-
able, chemotherapy was tried, and she received three
rounds of the vincristine, ifosfamide, doxorubicin, etopo-
side (VIDE) regimen. This proved of minimal benefit,
and external beam radiotherapy was administered to her
skull base (60Gy over 30 fractions). Two years after this,
tumour extension in her left neck was treated with rad-
ical radiotherapy. In the next couple of years, she devel-
oped visual disturbances in her left eye, initially as ‘zig-
zag’ lights and impairment of central vision, which rap-
idly progressed to blindness, probably as a combined
consequence of skull base disease progression and
delayed side effects from multiple treatments. At this
time, the progression of her intracranial disease left
management teams at a loss regarding further active
management.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Magnetic resonance images. (A) Axial T1-weighted, contrast-enhanced magnetic resonance images at time of first treatment,
showing the left cavernous sinus tumour and treatment isodoses as outlined in the Gamma KnifeW planning software. (B) Axial T1-weighted,
contrast-enhanced magnetic resonance images after 18 months.
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volume 7.5cm3) was treated with Gamma KnifeW radiosur-
gery (GKRS) two years ago (20Gy at 50% isodose), and our
patient showed excellent recovery (Figure 1A). Follow-up
one year later revealed no new side effects and a dramatic
reduction in the size of the treated tumour, further docu-
mented by magnetic resonance imaging at 18 months
(Figure 1B). However, this one-year follow-up also showed
tumour foci in the adjacent left frontal lobe and above her
right orbital apex (Figure 2), which were treated with a new
session of GKRS (20Gy at 50% isodose, total tumour volume
0.67cm3).
Discussion
Esthesioneuroblastoma is a very rare neuroectodermal
malignancy (approximate incidence one in 2.5 million),
arising from specialized olfactory cells [1]. It involves theFigure 2 Axial T1-weighted, contrast-enhanced magnetic resonance i
tumour foci in the left frontal lobe and above the right orbital apex.
isodoses are shown as outlined in the Gamma KnifeW planning software.junction of the upper nasal cavity and the anterior intra-
cranial fossa, typically extending upwards through the
cribiform plate of the ethmoid to various degrees of
extra-axial and brain involvement. In spite of its cell of
origin, anosmia is a rather uncommon presenting symp-
tom (5%). The most common complaints are nares
blockage (70%) and epistaxis (50%), followed in no par-
ticular order by persistent rhinorrhea, watery eye
through blockage of the lacrimal duct, and intracranial
signs like headache and visual disturbances [1,2]. Brain
imaging studies (computed tomography and magnetic
resonance imaging [MRI]) typically show a dumbbell-
shaped mass eroding across the cribiform plate, with
homogenous enhancement (cold spots signify intratu-
moural necrosis). Pathology shows neuroblastoma cells
arranged in a lobular architecture, within a continuum
of aggressiveness from Hyams grade I to grade IV (asmages one year after the first treatment, showing new, small
These were treated with a new session of radiosurgery. Treatment
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and areas of necrosis progress from absent to marked)
[3].
Several staging systems have been proposed. At the
time of stereotactic radiosurgery, our patient’s tumour
was Kadish stage C (‘spread beyond nasal and paranasal
cavities’) and grade IV according to other classifications
(Biller ‘unresectable tumour’; Dulguerov-Calcaterra,
‘tumour involving the brain’) [4-6].
There have been over 1000 reports of olfactory neuro-
blastoma since its description in 1924 [2,7]. Neverthe-
less, it remains exceedingly rare, and this may be the
main reason why there is still no therapeutic consensus
regarding the use and timing of different management
options including surgery, external beam radiotherapy
and chemotherapy. A report cited surgery as the only
treatment, restricting radiation’s role to palliation [4],
perhaps in an attempt to obviate the serious side effects
incurred by radical conventional radiotherapy of the cra-
niofacial junction, including blindness (which our patient
has also experienced) [8]. Others [5,9] emphasized the
complementary roles of both therapies, as the upper
limit of local recurrence ranges from 33% with multi-
modal management to 50% with surgery alone [2]. A
series by the Mayo Clinic [10] evaluating cisplatin-based
chemotherapy yielded a control rate of 30%; however,
the small sample size (10 patients) did not allow any
guidelines to be drawn. Currently, the five-year survival
is estimated at 40% for high-grade tumours and 80% for
low-grade tumours [1].
We are aware of only one other group in the world to
have reported the use of stereotactic radiosurgery for ol-
factory neuroblastoma [2,11,12]. The Graz (Austria)
group reported a series of 14 patients having received
upfront bimodal treatment: endoscopic surgery for the
nasal and paranasal component and GKRS for the intra-
cranial component. Margin doses between 15 and 34Gy
were used to treat tumour volumes up to 22cm3, achiev-
ing good long-term control with virtually no
radiosurgery-related side effects. Local tumour control
was 100%. While tumour recurrence at distant sites was
noted in five of their patients, only one needed a craniot-
omy and the other four were successfully managed by a
new session of GKRS.
We here report the GKRS management of recurrent
intracranial disease in a patient for whom all other
options - surgery, radiotherapy and chemotherapy - were
deemed exhausted. The sizeable tumour (7.5cm3) in her
left cavernous sinus showed an excellent response. The
new tumour foci identified on the one-year follow-up
MRI were managed by another session of GKRS, and
they also appeared to be stable six months after treat-
ment. We used a 20Gy dose as a previous report [2]
noted no significant differences in outcome for marginaldoses between 15 and 34Gy. Plan conformality did bene-
fit from the fact that our patient was already blind in her
left eye; that being said, we note same-dose GKRS
achieves excellent results with other cavernous sinus
tumours of even greater size (for example, meningi-
omas), for which careful planning to avoid afflicting the
visual pathways has been proven a definite possibility.
The very principle of GKRS, allowing delivery of a high
radiation dose in a single fraction, maximizing it to the
target while minimizing the radiation to surrounding tis-
sues, ensures good local control while maintaining a be-
nign side effect profile, preserving the best quality of life
possible for an oncology patient. Moreover, and perhaps
most importantly, it allows for procedure repeatability,
so that regular imaging and re-treatment of any new
intracranial lesions becomes an attractive option.
Conclusions
The current standard of care - surgery and radiation -
carries a high risk of morbidity and serious side effects
(visual and/or cognitive), while still leaving the patient at
risk for recurrence. Due to its low morbidity, non-
existent mortality and reasonable side effect profile,
GKRS is certainly an option to consider when dealing
with intracranial esthesioneuroblastoma. While we re-
port its value as a last resort for a patient who has
already exhausted surgery and chemoradiotherapy, fur-
ther experience is necessary to document its role as a
valid primary option for intracranial olfactory
neuroblastoma.
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